Skip to main content

Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV

Medically reviewed by Carmen Pope, BPharm. Last updated on April 30, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter published online April 30 in the Annals of Internal Medicine.

Jordan E. Lake, M.D., from UTHealth Houston, and colleagues designed a pilot study to examine the effect of semaglutide on magnetic resonance imaging-proton density fat fraction-quantified intrahepatic triglycerides (IHTG) in PWH and MASLD. Eligible participants were aged 18 years or older and had suppressed HIV-1 RNA while using antiretroviral therapy. The per-protocol analysis included 49 of 51 participants with central adiposity, insulin resistance or prediabetes, and steatotic liver disease.

The researchers observed clinically significant reductions in IHTG over 24 weeks. Overall, 29 and 58 percent of participants had complete resolution of MASLD and a relative reduction of IHTG of at least 30 percent, respectively. Anthropometric measurements, glucose regulation markers, and triglyceride concentrations also improved significantly. Semaglutide 1 mg weekly was tolerated by all participants. Grade 1 gastrointestinal symptoms were the most common adverse events.

"In summary, semaglutide, 1 mg weekly, is an effective therapy for MASLD in PWH and shows evidence of broader cardiometabolic benefit," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted April 2024

Read this next

Childhood Physical Activity Levels Tied to Risk for Liver Disease in Young Adults

WEDNESDAY, June 19, 2024 -- Increasing physical activity during childhood may independently lower the risk for liver disease in young adulthood, according to a study published...

Survodutide Tied to Significant Improvement in Fatty Liver Disease

MONDAY, June 17, 2024 -- Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in...

Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis

THURSDAY, June 13, 2024 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.